In this study, the infusion of CART-HER2 cells was safe without significant adverse events, one possible important reason is the dose-escalation infusion strategy in which well-cultured CART cells were harvested partially per day for infusion in 3–5 successive days instead of one-off infusion of the total CART cells, which may facilitate to avoid severe acute allergy or other CART cell infusion-related toxicities that may impair the function of pulmonary, cardiac, and other organs. This evidence concerns the gene ERBB2 and allergic disease.